13.05.2024  15:01:14 Zm. -1,05 Wolumen Bid15:01:14 Ask15:01:14 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
73,50CHF -1,41% 63 146
Obrót: 4,72 mln
73,50Wolumen Bid: 309 73,75Wolumen Ask: 145 1,18 mldCHF - 12,26

Opis działalności

Operating under the "Zur Rose" and "DocMorris" brands, the Swiss-based Zur Rose Group is one of Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical practitioners. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management in order to increase therapy safety. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry. The Zur Rose Group serves the Swiss market from Frauenfeld, Switzerland. In Germany and Austria, the Group operates through subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany). Furthermore, it holds a majority interest in BlueCare in Winterthur, one of the leading providers of networking systems in the Swiss healthcare market.
 

Zarząd & Rada nadzorcza

CEO
Walter Hess
Zarząd
Marcel Ziwica, David Masó, Madhu Nutakki, Matthias Peuckert, Kaspar Niklaus
Rada nadzorcza
Dr. Christian Mielsch, Florian Seubert, Prof. Dr. Andréa Belliger, Prof. Dr. Volker Amelung, Prof. Stefan Feuerstein, Walter Oberhänsli
 

Dane firmy

Nazwa: Zur Rose Group AG
Adres: Walzmühlestrasse 60,CH-8500 Frauenfeld
Telefon: +41-52-7240020
Fax: +41-52-7240015
E-mail: info@zurrose.com
Internet: www.zurrosegroup.com
Przemysł: Dobra konsumpcyjne
Sektor: Handel Detaliczny
Podsektor: -
Koniec roku finansowego: 31.12
Free float: 75,60%
Data IPO: 06.07.2017

Relacje inwestorskie

Nazwa: Marcel Ziwica
Telefon: +41-52-7240064
Fax: -
E-mail: marcel.ziwica@zurrose.com

Kalendarz korporacyjny

Tydz. 34 | 20.08.2024 Raport okresowy/2. kwartał
Tydz. 42 | 15.10.2024 Raport okresowy/3. kwartał
 

Główni akcjonariusze

Inne
 
85,37%
Frank M. Sands
 
4,93%
Patrick Schmitz-Morkramer Patrick Bierbaum
 
3,79%
Benjamin Leslie Levine
 
3,02%
BlackRock, Inc
 
2,89%